140 results about "Calcitriol" patented technology

Sprayable, anhydrous and physically/chemically stable dermatological/pharmaceutical compositions, well suited for the treatment of a variety of dermatological disorders, notably psoriasis, contain: a) a therapeutically effective amount of a solubilized corticoid, notably dissolved clobetasol propionate; b) a therapeutically effective amount of a solubilized vitamin D derivative, notably dissolved calcitriol; and c) an oily phase which comprises one or more oils; formulated into d), a sprayable and topically applicable, dermatologically/pharmaceutically acceptable vehicle therefor.

The endometriosis treatment protocol provides for administering to a female patient in need of treatment for endometriosis a pharmaceutical composition in a form suitable for vaginal or rectal delivery having a pharmaceutically effective amount of an aromatase inhibitor, which may be either a steroid or non-steroidal. The pharmaceutical composition may be formed as a vaginal suppository, a rectal suppository, a vaginal gel, a rectal gel, a vaginal cream or a rectal cream. The pharmaceutical composition may optionally have pharmaceutically effective amounts of progesterone and calcitriol, and may be administered in combination with an oral COX-2 inhibitor. Alternatively, the pharmaceutical composition comprises an aromatase inhibitor administered vaginally or rectally and is administered in combination with oral calcitriol and the oral COX-2 inhibitor. The aromatase inhibitor is either steroidal or non-steroidal.

Methods and compositions for the treatment of pulmonary disease using inhalation are provided. In particular, the present disclosure provides novel methods and compositions for treating pulmonary diseases such as asthma, bronchitis, COPD, emphysema, lung cancer, pneumonia and pulmonary edema. In addition, the present disclosure provides novel methods and compositions for treating complications associated with pulmonary disease such as corticosteroid resistance and pulmonary tissue destruction. The compositions of the present disclosure comprise corticosteroid resistance agents including but not limited to vitamin D, calcitriol and equivalents thereof. The compositions of the present disclosure also comprise alveolar development and maintenance agents including but not limited to vitamin A, ATRA and equivalents thereof. The present invention provides effective administration of therapeutic agents to specific airways of the lungs by utilizing controlled site delivery.

Topically applicable, anhydrous, hydrophobic and physically/chemically stable dermatological/pharmaceutical oleaginous ointments having effective release/penetration capacity and also having therapeutically effective amounts of calcitriol and clobetasol 17-propionate solubilized therein, are well suited for the treatment of psoriasis.

The present invention relates to a pharmaceutical composition for the treatment of metabolic bone disease and the method of preparation thereof, and more particularly, to an improved pharmaceutical composition for the therapeutic treatment of metabolic disease and the method of preparation thereof, wherein said composition is prepared as a composite pharmaceutical agent which comprises calcitriol; which reduces the rate of spine fractures and increases bone density; alendronate, a bone resorption inhibitor, as two main active ingredients in an optimal mixing ratio to exert the greatest synergistic therapeutic effect; and adequate amount of other additives such as a resorption fortifier of alendronate. Thereof, the pharmaceutical composition according to the present invention can inhibit hypercalcemia caused when administered by calcitriol alone, compensate the inhibitory activity of bone remodeling caused by alendronate due to the presence of calcitriol, and improve drug compliance associated with the usual difficulty in administration as well as a side effect in esophagus, thus effectively preventing the occurence of osteoporosis.

The invention relates to a softgel containing calcitriol, and the softgel comprises the following raw materials: calcitriol, middle chain triglyceride, 2,6-di-tert-butyl-4-methylphenol and butylated hydroxyanisole. The rubber of the softgel contains gelatin, glycerin, a light-screening agent and a colouring agent, and sorbitol is not contained. The preferably calcitriol amount is 0.25 mum/pill-1.00 mum/pill, middle chain triglyceride amount is 0.10g/pill-1.00g/pill, the amount of 2,6-di-tert-butyl-4-methylphenol and butylated hydroxyanisole respectively account 0.0030%-0.0090% of weight of middle chain triglyceride. The softgel containing calcitriol has the advantages of simple preparation, little impurity increase in a storage process, stable quality and high security.

Topically applicable pharmaceutical compositions useful for the treatment of psoriasis contain respective amounts of calcitriol and clobetasol propionate permitting a once-per-day effective regimen of topical application onto the part or parts of the skin affected by psoriasis.

The invention discloses a vitamin D analog preparation and a preparation method thereof. The invention aims to solve the problems that a conventional preparation method of vitamin D analog has difficulty in meeting the uniformity requirement and during the granulation process, drugs are converted and degraded easily. For the first time, a double screw extrusion technology is used to prepare a solid preparation of vitamin D analog. Various vitamin D analogs are taken as model drugs, on the basis that a preparation technology of solid preparations is deeply researched, alfacalcidol, eldecalcitol, or calcitriol is chosen to prepare the solid preparation by using a double screw extruding machine; the uniformity meets the pharmacopeia requirements; the drug stability is obviously enhanced, andthe drug quality is greatly improved.

Prophylactic or therapeutic treatment to inhibit the development or progress of multiple sclerosis symptoms is provided by providing intermittently administered elevated doses of calcitriol, sufficiently infrequently to avoid hypercalcemia. Such methods may include maintaining at least about a normal blood level of vitamin D₃ as evidenced by a 25-(OH)D₃ level of at least about 50 nmol/L.

Anhydrous sprayable physically and chemically stable pharmaceutical/dermatological compositions containing a vitamin D derivative as an active pharmaceutical ingredient, particularly calcitriol, and an oily phase are formulated into a physiologically-acceptable medium, and are useful for the treatment of a variety of conditions and afflictions, notably psoriasis.

The invention relates to a calcitriol emulsion and a preparation method thereof. The emulsion is prepared from the following ingredients in percentage by weight: 0.0005% of calcitriol, 0.7-1.2% of meglumine, 12-18% of polyethylene glycol 400, 1.5-2.5% of polyethylene glycol 6000, 0.5-30% of vegetable oil, 4.0% of emulsifying agent, 1.0% of coemulsifier and the balance of water for injection. According to the emulsion, the content of calcitriol is remarkably increased, so that the drug dosage is reduced; and the stability of calcitriol to light and air is improved, and the bioavailability of calcitriol is also remarkably improved.

The invention relates to a calcitriol injection and a preparation method thereof. The injection is prepared from the following ingredients in percentage by weight: 0.0005% of calcitriol, 1.2-1.6% of meglumine, 18-24% of polyethylene glycol 400, 1.2-1.7% of polyethylene glycol 6000, 0.1% of antioxidant, an appropriate amount of isotonicity regulator and the balance of water for injection. According to the injection, the content of calcitriol is remarkably increased, so that the drug dosage is reduced; and the stability of calcitriol to light and air is improved, and the bioavailability of calcitriol is also remarkably improved.

The invention relates to a method and a device for preparing calcitriol by utilizing photochemical reaction. 5,6- trans isomer aborted as impurity in the existing production process of the calcitriol is converted into the calcitriol through the photochemical reaction, thereby the production yield of the calcitriol is increased by 50 percent, and the method for preparing the calcitriol by utilizing the photochemical reaction is carried out in a reaction device. The major structure comprises a reactor containing a clamping sleeve, a quartz glass light tube low-pressure mercury light and a low-temperature cooling liquid recycle pump, wherein the reactor is internally provided with the clamping sleeve, an inner sleeve adopts heat-resistant quartz glass, and an outer sleeve adopts the heat-resistant quartz glass the outer wall of which is plated with silver mirror; the mercury light is arranged in the inner sleeve of the reactor; reaction liquid is arranged in the outer sleeve of the reactor; and the outer sleeve of the reactor is provided with an upper outlet and a lower outlet. The preparation method has simple technical process, easy control of reaction, high product yield and strong environmental protection, and the device has simple structure, convenient operation, energy saving and good product yield.

Topically applicable pharmaceutical gel, cream, lotion, solution or ointment compositions contain synergistically effective amounts of a) calcitriol and b) clobetasol propionate, formulated into a topically applicable, pharmaceutically acceptable medium therefor, and are useful for the treatment of such dermatological afflictions or conditions as psoriasis, atopic dermatitis, contact dermatitis and seborrhoeic dermatitis.

The invention relates to a preparation method of calcitriol which is a compound material, belonging to the technical field of preparation of drug synthesis and organic compound synthesis. In the invention, the calcifediol is taken as raw material, a majority of produced impurities in the chemical reaction process are removed through medium-pressure liquid phase chromatography, wherein calcifediol carried out sulfonylation and ring closing on toluene, and the medium-pressure liquid phase chromatography is used for removing the impurities; products carry out oxidation reaction, medium-pressure chromatographic column separates and removes the impurities, ring opening is carried out, medium-pressure liquid phase is added for coarsely separating stereoisomeride, and at last the products separated by high-pressure liquid phase chromatography is hydrolyzed and refined to obtain the calcitriol. The invention is reasonably selected, comprehensively applies the advantages of the medium and high pressure liquid phase chromatography, has simple detaching method, can effectively remove the impurities, thoroughly separates the stereoisomeride, has high purity of the calcitriol obtained from separation, has a productive rate of 40 percent, high yield and low cost, shortens production period, is suitable for industrial scale, has application prospect, and provides a time-saving, economic and efficient method for the separation and the preparation of chiral compounds.

The invention relates to a calcitriol solution and a preparation method thereof. The solution is prepared from the following ingredients in percentage by weight: 0.0005% of calcitriol, 0.9-1.2% of meglumine, 27-30% of polyethylene glycol 400, 12-14% of polyethylene glycol 6000, 0.2% of antioxidant, 0.5% of flavoring agent and the balance of distilled water. Compared with the prior art, the solution has the advantages that the content of calcitriol is remarkably increased, so that the drug dosage is reduced; and the stability of calcitriol to light and air is improved, and the bioavailability of calcitriol is also remarkably improved.

The invention relates to a calcitriol pellet and a preparation method thereof. The pellet is prepared from the following ingredients in percentage by weight: 0.0005% of calcitriol, 2.0-4.0% of meglumine, 1.2-1.8% of polyethylene glycol 400, 15-25% of polyethylene glycol 6000, 50.0-70.0% of filler, 5.0-10.0% of disintegrant and an appropriate amount of binder. According to the pellet, the content of calcitriol is remarkably increased, so that the drug dosage is reduced; and the stability of calcitriol to light and air is improved, and the bioavailability of calcitriol is also remarkably improved.

The invention discloses a method and a system for determining a dissolution rate of calcitriol soft capsules. The method comprises the following steps: (1) performing dissolution treatment on to-be-determined calcitriol soft capsules by utilizing a dissolution medium so as to conveniently obtain dissolution liquor, wherein the dissolution medium is 4.0wt% of SDS aqueous solution; (2) detecting thecontent of calcitriol in the dissolution liquor; (3) determining the dissolution rate of the calcitriol soft capsules based on the detection result of the to-be-determined calcitriol soft capsules inthe step (2). According to the method for determining the dissolution rate of the calcitriol soft capsules provided by the invention, an in-vivo dissolution behavior can be effectively simulated to determine the dissolution rate of the calcitriol soft capsules.

The increased use of sunscreens, while limiting damage to the DNA, may promote cancer growth by preventing vitamin D synthesis in the skin. According to the present invention, the beneficial effects of UV radiation are obtained by incorporating vitamin D into the topical sunscreen. Application of the sunscreen prevents the harmful effects of UV radiation and the included vitamin D is activated by the skin to calcitriol for cancer prevention. Because calcitriol also promotes cellular growth and differentiation, the topical sunscreen with vitamin D may be of benefit for photoaging.

Dermatological/pharmaceutical compositions contain lipid vesicles dispersed in a hydrophilic phase, such vesicles including at least one vitamin D compound and particularly calcitriol, and are useful for the treatment of dermatological pathologies, notably psoriasis.

The invention provides a calcitriol liquid hard capsule, a method for preparing the same and application of the calcitriol liquid hard capsule. Every 1000 calcitriol liquid hard capsules comprise 0.25-0.5 mg of calcitriol, 140-170 g of oil-based matrixes and 25-40 mg of antioxidants. The method includes mixing the antioxidants and the oil-based matrixes with one another to obtain first mixtures; stirring and dissolving the first mixtures and then adding the calcitriol into the first mixtures to obtain second mixtures; continuing to stir and dissolve the second mixtures and then vacuumizing and degassing the second mixtures; filling hard capsule shells with the mixtures to obtain the calcitriol liquid hard capsule. The calcitriol liquid hard capsule, the method and the application have the advantages that the calcitriol liquid hard capsule can be effectively applied to treating post-menopause and senile osteoporosis, chronic renal failure and the like; the content uniformity of the calcitriol liquid hard capsule which is a medicine can be improved, the calcitriol liquid hard capsule is good in stability, long in quality guarantee period, high in bioavailability, low in cost and convenient to administer, and accordingly the calcitriol liquid hard capsule, the method and the application have obvious merits.